Champions Oncology, Inc. (CSBR) News
Filter CSBR News Items
CSBR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CSBR News Highlights
- For CSBR, its 30 day story count is now at 2.
- Over the past 2 days, the trend for CSBR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG are the most mentioned tickers in articles about CSBR.
Latest CSBR News From Around the Web
Below are the latest news stories about CHAMPIONS ONCOLOGY INC that investors may wish to consider to help them evaluate CSBR as an investment opportunity.
Champions Oncology Reports Quarterly Revenue of $12.8 MillionChampions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2023, ended January 31, 2023. |
Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). |
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2023 Earnings Call TranscriptChampions Oncology, Inc. (NASDAQ:CSBR) Q2 2023 Earnings Call Transcript December 13, 2022 Operator: Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for you questions and comments after […] |
Champions Oncology Reports Record Quarterly Revenue of $14.3 MillionChampions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its second quarter of fiscal 2023, ended October 31, 2022. |
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). |
Champions Oncology Reports Record Quarterly Revenue of $13.7 MillionChampions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2023, ended July 31, 2022. |
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). |
What Type Of Shareholders Make Up Champions Oncology, Inc.'s (NASDAQ:CSBR) Share Registry?If you want to know who really controls Champions Oncology, Inc. ( NASDAQ:CSBR ), then you'll have to look at the... |
We Ran A Stock Scan For Earnings Growth And Champions Oncology (NASDAQ:CSBR) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story... |
Champions Oncology Reports Quarterly Revenue of $12.9 MillionChampions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2022. |